Does Insulin Resistance Cause RLS?
Insulin resistance does not directly cause RLS, but there is a significant association between the two conditions, with insulin resistance and glucose metabolism abnormalities appearing substantially more common in patients with idiopathic RLS than in the general population.
The Evidence for Association
The relationship between insulin resistance and RLS is correlative rather than clearly causal:
Impaired glucose tolerance (IGT) is markedly elevated in idiopathic RLS patients. A 2009 study found that 41% of RLS patients had IGT compared to only 18% of controls, and 19% had newly diagnosed diabetes versus 6% of controls (p=0.002) 1. This suggests glucose metabolism dysfunction is frequently present even when fasting glucose appears normal.
The triglyceride-glucose (TyG) index, a marker of insulin resistance, correlates with RLS severity. A 2024 study demonstrated that the TyG index was significantly higher in RLS patients and showed positive correlation with disease duration and severity 2. This provides more direct evidence linking insulin resistance markers to RLS pathology.
Diabetes substantially increases RLS risk. A 2022 pooled analysis of 835,986 participants found that 25% of people with diabetes have RLS, and diabetics have nearly double the risk of developing RLS compared to non-diabetics (OR 1.98,95% CI 1.66-2.34) 3.
The Mechanism Remains Unclear
The directionality and mechanism of this relationship is uncertain:
- Insulin resistance could contribute to RLS through metabolic or neurological pathways
- Chronic sleep disruption from RLS could promote insulin resistance development 4
- Diabetic peripheral neuropathy may mimic or coexist with RLS, complicating diagnosis 5
- Shared underlying pathophysiology may link both conditions
Importantly, insulin resistance itself was not significantly different between RLS patients and controls in at least one study using HOMA-Index 1, suggesting the relationship may be more complex than simple insulin resistance causing RLS.
Clinical Implications
Screen all idiopathic RLS patients for glucose metabolism abnormalities, even with normal fasting glucose. Consider a 2-hour oral glucose tolerance test (OGTT) in RLS patients to identify prediabetes or undiagnosed diabetes 1.
The most recent 2025 AASM guidelines for RLS treatment 6 do not specifically address insulin resistance as a causative factor or treatment target, focusing instead on iron status, alpha-2-delta ligands (gabapentin, pregabalin), and other symptomatic treatments. This guideline omission further suggests insulin resistance is an associated condition rather than a primary cause requiring specific intervention.
When RLS coexists with diabetic neuropathy, prioritize glucose control first, then treat RLS symptoms with alpha-2-delta ligands like gabapentin or pregabalin 5, which address both neuropathic pain and RLS symptoms.